RecruitingNot ApplicableNCT06574620

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer

Sponsor

British Columbia Cancer Agency

Enrollment

200 participants

Start Date

Nov 28, 2025

Study Type

INTERVENTIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Borderline Resectable Pancreatic Ductal Adenocarcinoma Locally Advanced Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Ductal Adenocarcinoma

Summary

The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC? * Can the genetic test results provide information about how a tumour will respond to or resist treatment? Participants will: * Receive standard chemotherapy to treat their cancer. * Provide samples of their blood, tissue, and fluid for genetic testing. * Visit the clinic every 4 weeks for check-ups and tests. * Complete questionnaires every 12 weeks.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects tumor DNA and proteins from people with pancreatic cancer (specifically pancreatic ductal adenocarcinoma, or PDAC) to better understand how their cancer responds or becomes resistant to treatment. Samples are collected during a standard laparoscopic procedure. **You may be eligible if...** - You are 18 or older - You have been diagnosed with resectable, borderline resectable, or locally advanced pancreatic cancer - You are medically fit and scheduled for a laparoscopic procedure as standard care - You are enrolled (or can be enrolled) in the Personalized Oncogenomics (POG) Program at BC Cancer (Canada) **You may NOT be eligible if...** - You are not fit for a laparoscopic procedure - You are unable to give informed consent - You are not able to participate in the POG program Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICGenetic testing

Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.

PROCEDUREOptional biopsy

Optional collection of tumour tissue and normal tissue after the last dose of treatment.

PROCEDURETissue collection

Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.

Locations(1)

BC Cancer

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06574620

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

NCT071570334 locations

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121279 locations

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT067107567 locations